SCHEMBL1640172

SCHEMBL1640172

Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCN(Cc3nccs3)CC2)n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 18/20 0.73
CSNK1D P48730 3/20 0.70
CSNK1E P49674 2/20 0.70
MAPK13 O15264 2/20 0.66
MAPK12 P53778 2/20 0.66
MAPK11 Q15759 2/20 0.66
EGFR P00533 1/20 0.66
KCNH2 Q12809 1/20 0.66
RIPK2 O43353 1/20 0.64
DYRK3 O43781 1/20 0.64
PRKD3 O94806 1/20 0.64
MAP4K4 O95819 1/20 0.64
PRKCG P05129 1/20 0.64
LCK P06239 1/20 0.64
LYN P07948 1/20 0.64
RET P07949 1/20 0.64
PIM1 P11309 1/20 0.64
PRKACA P17612 1/20 0.64
MAPK1 P28482 1/20 0.64
FLT4 P35916 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15203578 0.95 MAPK14 (0.66) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1641007 0.86 MAPK14 (0.68) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1640760 0.85 MAPK14 (0.81) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1639775 0.85 MAPK14 (0.75) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1641015 0.85 MAPK14 (0.67) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL4585095 0.85 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1640738 0.84 MAPK14 (0.71) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL20550753 0.84 MAPK14 (0.91) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL7610170 0.83 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1641003 0.82 MAPK14 (0.79) MAPK14CSNK1DCSNK1EMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102686580-B imidazole derivatives as casein kinase inhibitors PFIZER 2014-09-10 CN disclosed
EP-2493876-B1 IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS PFIZER (US) 2014-02-12 EP disclosed
US-8518944-B2 Compounds as casein kinase inhibitors PFIZER INC. (US) 2013-08-27 US disclosed
CN-102686580-A Imidazole derivatives as casein kinase inhibitors PFIZER 2012-09-19 CN disclosed
US-20110098272-A1 Novel Compounds As Casein Kinase Inhibitors PFIZER INC 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098272-A1 Novel Compounds As Casein Kinase Inhibitors CSNK1A1, CSNK1A1L, CSNK1G1 MAPK14 169/4885CSNK1D 12/4885CSNK1E 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.